Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years
S. Negrin Dastis1
, E. François2
, J. Deviere2
, A. Hittelet2
, A. Ilah Mehdi2
, M. Barea2
, J. -M. Dumonceau1
1Gastroenterology and Hepatology Service, Geneva University Hospitals, Geneva, Switzerland.
2Medical-Surgical department of gastroenterology, hepatopancreatology and Digestive oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Background and study aims: To determine long-term outcome after treatment with an intragastric balloon for 6 months, with no structured weight maintenance program offered after balloon removal.
Patients and methods: 100 consecutive overweight/obese individuals (mean body mass index [BMI] 35.0 ± 5.6 kg/m2) were prospectively followed after endoscopic implantation of a saline-filled intragastric balloon; 97 completed final follow-up at a mean of 4.8 ± 1.6 years. Successful intragastric balloon therapy was defined as weight loss at 6 months of ≥ 10 % of weight at baseline, that remained ≥ 10 % until 2.5 years, without bariatric surgery. All analyses followed intention-to-treat principles.
Results: At 6 months, mean weight loss was 12.6 ± 8.3 kg, 63 individuals had ≥ 10 % baseline weight loss; no severe morbidity was detected. During the first and second years following intragastric balloon removal, mean body mass increased by 4.2 ± 6.8 and 2.3 ± 6.0 kg, respectively (P < 0.001 for both year-on-year comparisons). At 2.5 years, intragastric balloon therapy had been successful in 24 participants. At final follow-up (4.8 ± 1.6 years), 28 had ≥ 10 % baseline weight loss, 35 had undergone bariatric surgery (60 % had preoperative mass higher than baseline), and 3 were lost to follow-up; the 34 remaining had lost 1.5 ± 5.8 kg compared with baseline. During follow-up, 13 had a second intragastric balloon implanted and 13 took sibutramine for short periods.
Conclusion: Intragastric balloon therapy was relatively innocuous and associated with successful weight loss and maintenance at 2.5 years in a quarter of participants. It represents a valid option for weight loss.
References
1 World Health Organization .Obesity: Preventing and managing the global epidemic. WHO Obesity Technical Report Series 894; World Health Organization, Geneva, Switzerland. 2000
2
Anonymous .
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. National Institutes of Health.
Obes Res.
1998;
6 (Suppl 2)
51S-209S
3
Schapiro M, Benjamin S, Blackburn G. et al .
Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19–21 1987.
Gastrointest Endosc.
1987;
33
323-327
4
Genco A, Cipriano M, Bacci V. et al .
BioEnterics intragastric balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients.
Int J Obes.
2006;
30
129-133
5
Martinez-Brocca M A, Belda O, Parejo J. et al .
Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity.
Obes Surg.
2007;
17
649-657
6
Mathus-Vliegen E M, Tytgat G N.
Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up.
Gastrointest Endosc.
2005;
61
19-27
7
Zago S, Kornmuller A M, Agagliati D. et al .
[Benefit from bio-enteric Intra-gastric balloon (BIB) to modify lifestyle and eating habits in severely obese patients eligible for bariatric surgery].
Minerva Medica.
2006;
97
51-64
9
Heshka S, Anderson J W, Atkinson R L. et al .
Weight loss with self-help compared with a structured commercial program: a randomized trial.
JAMA.
2003;
289
1792-1798
13
Apfelbaum M, Vague P, Ziegler O. et al .
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.
Am J Med.
1999;
106
179-184
14
Wadden T A, Berkowitz R I, Womble L G. et al .
Randomized trial of lifestyle modification and pharmacotherapy for obesity.
N Engl J Med.
2005;
353
2111-2120
16
James W P, Astrup A, Finer N. et al .
Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance.
Lancet.
2000;
356
2119-2125
17
Herve J, Wahlen C H, Schaeken A. et al .
What becomes of patients one year after the intragastric balloon has been removed?.
Obes Surg.
2005;
15
864-870
18
Doldi S B, Micheletto G, Perrini M N, Rapetti R.
Intragastric balloon: another option for treatment of obesity and morbid obesity.
Hepato-Gastroenterology.
2004;
51
294-297
21
Svetkey L P, Stevens V J, Brantley P J. et al .
Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial.
JAMA.
2008;
299
1139-1148
23
Eddy D M, Schlessinger L, Kahn R.
Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
Ann Intern Med.
2005;
143
251-264
28
Machytka E, Klvana P, Hanuskova L, Janik I.
Use of pharmacotherapy for long-term maintenance of weight loss following explantation of intragastric balloon (BIB).
Gut.
2007;
57
A290
29
Padwal R, Kezouh A, Levine M, Etminan M.
Long-term persistence with orlistat and sibutramine in a population-based cohort.
Int J Obes.
2007;
31
1567-1570
32
Dhruva S S, Redberg R F.
Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions.
Arch Intern Med.
2008;
168
136-140
